CARLSBAD, Calif., Feb. 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately $200 million..

加利福尼亚州卡尔斯巴德，2024年2月2日/PRNewswire/--Tyra Biosciences，Inc.（纳斯达克：Tyra），一家临床阶段的生物技术公司，专注于开发下一代精准药物，这些药物针对成纤维细胞生长因子受体（FGFR）生物学的巨大机会，今天宣布，它已与机构和合格投资者签订了证券购买协议，以私募融资（PIPE）出售证券，总收益约为2亿美元。。

The financing was led by RA Capital Management, with participation by new and existing institutional investors, including Boxer Capital, BVF Partners, Nextech Invest Ltd (on behalf of one or more funds managed by it), OrbiMed, 5AM Ventures, a large investment management firm and a life-sciences focused institutional investor..

融资由RA Capital Management牵头，新的和现有的机构投资者参与，包括Boxer Capital、BVF Partners、Nextech investment Ltd（代表其管理的一个或多个基金）、OrbiMed、5AM Ventures、大型投资管理公司和专注于生命科学的机构投资者。。

'We appreciate the support of RA Capital and our outstanding group of current and new investors as we further our mission of developing next-generation precision medicines that target FGFR biology,' said Todd Harris, CEO of TYRA. 'The additional funding strengthens our balance sheet at a time of strong momentum.

TYRA首席执行官托德·哈里斯（ToddHarris）说：“我们感谢RA Capital和我们杰出的现有和新投资者团队的支持，因为我们进一步致力于开发针对FGFR生物学的下一代精准药物。”在强劲的势头下，额外资金加强了我们的资产负债表。

We are focused on developing TYRA-300, an oral FGFR3-selective inhibitor, to become a best-in-class agent for achondroplasia, NMIBC and metastatic urothelial carcinoma, while advancing TYRA-200 and leveraging our SNÅP platform to discover new drug candidates.'.

我们专注于开发口服FGFR3选择性抑制剂TYRA-300，成为软骨发育不全，NMIBC和转移性尿路上皮癌的最佳药物，同时推进TYRA-200并利用我们的SNÅP平台发现新的候选药物。”。

In the PIPE, TYRA is selling an aggregate of approximately 15.4 million shares of its common stock (or pre-funded warrants in lieu thereof) at a price of $13.01 per share (or $13.009 per pre-funded warrant). The pre-funded warrants will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire.

在管道中，TYRA以每股13.01美元（或每股13.009美元）的价格出售了总计约1540万股普通股（或替代其的预支认股权证）。预先出资的认股权证的行权价格为每股普通股0.001美元，可立即行权且不会到期。

The PIPE is expected to close on February 6, 2024, subject to customary closing conditions. The financing was priced at-the-market under Nasdaq rules..

根据惯例关闭条件，管道预计将于2024年2月6日关闭。融资是根据纳斯达克规则在市场上定价的。。

TYRA intends to use the net proceeds from the PIPE to advance the clinical development of TYRA-300 and TYRA-200, to advance its preclinical programs, and for drug discovery, working capital and general corporate purposes.

TYRA打算利用管道的净收益来推进TYRA-300和TYRA-200的临床开发，推进其临床前项目，以及用于药物发现、营运资金和一般企业目的。

The securities described above have not been registered under the Securities Act of 1933, as amended. Accordingly, these securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act.

上述证券尚未根据经修订的《1933年证券法》进行登记。因此，除非根据有效的登记声明或《证券法》登记要求的适用豁免，否则不得在美国发售或出售这些证券。

TYRA has agreed to file a registration statement with the Securities and Exchange Commission (SEC) registering the resale of the shares of common stock and shares of common stock issuable upon the exercise of the pre-funded warrants issued in this PIPE..

TYRA已同意向美国证券交易委员会（SEC）提交一份登记声明，登记普通股股份的转售以及行使在此管道中发行的预融资认股权证后可发行的普通股股份。。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction..

本新闻稿不构成出售或招揽购买这些证券的要约，也不构成在根据任何该等司法管辖区的证券法注册或取得资格之前，在任何州或其他司法管辖区出售这些证券是非法的。。

About Tyra Biosciences

关于Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.

Tyra Biosciences，Inc.（纳斯达克股票代码：Tyra）是一家临床阶段生物技术公司，专注于开发针对FGFR生物学巨大机遇的下一代精准药物。该公司的内部精密医学平台SNÅP通过迭代分子SNÅPshots实现了快速而精确的药物设计，这些分子SNÅPshots有助于预测最有可能导致对现有疗法产生获得性耐药的基因改变。

TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA..

TYRA最初的重点是应用其加速的小分子药物发现引擎来开发靶向肿瘤学和基因定义条件下的疗法。TYRA总部位于加利福尼亚州卡尔斯巴德。。

For more information about our science, pipeline and people, please visit https://tyra.bio/and engage with us on LinkedIn.

有关我们的科学、管道和人员的更多信息，请访问https://tyra.bio/and在LinkedIn上与我们联系。

Forward Looking Statements

前瞻性声明

TYRA cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: statements related to: the timing, size and expectation of the closing of the PIPE; expectations regarding market conditions, the satisfaction of customary closing conditions related to the PIPE and the anticipated use of proceeds therefrom; and the potential to discover and develop next-generation precision medicines and develop a best-in-class agent.

TYRA提醒您，本新闻稿中关于非历史事实的声明是前瞻性声明。前瞻性陈述基于我们目前的信念和期望，包括但不限于：与以下相关的陈述：管道关闭的时间、规模和期望；对市场状况的预期、与管道相关的惯例关闭条件的满足情况以及由此产生的收益的预期用途；以及发现和开发下一代精准药物和开发一流代理的潜力。

Such forward-looking statements involve substantial risks and uncertainties that could cause our actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by TYRA that any of its plans will be achieved.

此类前瞻性声明涉及重大风险和不确定性，可能导致我们的实际结果、业绩或成就与前瞻性声明明示或暗示的结果、业绩或成就存在重大差异。纳入前瞻性声明不应被视为TYRA表示其任何计划都将实现。

Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed financing; we are early in our development efforts and the approach we are taking to discover and develop drugs based on our SNÅP platform is novel and unproven and it may never lead to product candidates that are successful in clinical development or approved products of commercial value; and other risks described in our prior press releases and filings with the SEC, including under the heading 'Risk Factors' in our annual report on Form 10-K and any subsequent filings with the SEC.

由于我们业务中固有的风险和不确定性，实际结果可能与本新闻稿中所述不同，包括但不限于：与市场条件相关的风险和不确定性以及与拟议融资相关的惯例交割条件的满足程度；我们处于开发工作的早期阶段，我们正在基于SNÅP平台发现和开发药物的方法是新颖且未经证实的，它可能永远不会导致在临床开发中成功的候选产品或具有商业价值的批准产品；以及我们之前的新闻稿和向SEC提交的文件中描述的其他风险，包括我们在10-K表格年度报告中的“风险因素”标题下以及随后向SEC提交的任何文件。

You are cautioned not to .

警告你不要这样做。

Contact:Amy Conrad[email protected]

联系人：艾米·康拉德[受电子邮件保护]

SOURCE Tyra Biosciences

资料来源：Tyra生物科学